Journal ArticleDOI
Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
Patrick Marcellin,Ferruccio Bonino,George K. K. Lau,Patrizia Farci,Cihan Yurdaydin,Teerha Piratvisuth,R. Jin,Selim Gürel,Zhi-Meng Lu,Jian Wu,M. Popescu,Stephanos J. Hadziyannis +11 more
Reads0
Chats0
TLDR
The increased rate of HBsAg clearance in patients with HBeAg-negative chronic hepatitis B supports the use of peginterferon alpha-2a as a first-line treatment.About:
This article is published in Gastroenterology.The article was published on 2009-06-01. It has received 309 citations till now. The article focuses on the topics: Lamivudine & Peginterferon alfa-2a.read more
Citations
More filters
Journal ArticleDOI
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
Shiv Kumar Sarin,Manoj Kumar,George K. K. Lau,Zaigham Abbas,Henry Lik-Yuen Chan,Chien-Jen Chen,Ding-Shinn Chen,Huey-Ling Chen,Pei-Jer Chen,Rong-Nan Chien,Abdul Kadir Dokmeci,Edward Gane,J L Hou,Wasim Jafri,Jidong Jia,J. H. Kim,Ching-Lung Lai,Hon Cheung Lee,Seng Gee Lim,Chun-Jen Liu,Stephen Locarnini,M. Al Mahtab,Rosmawati Mohamed,Masao Omata,Jun Yong Park,Teerha Piratvisuth,Barjesh Chander Sharma,Jose D. Sollano,Fu-Sheng Wang,Lai Wei,Man-Fung Yuen,Shusen Zheng,Jia-Horng Kao +32 more
TL;DR: The final clinical practice guidelines and recommendations for the optimal management of chronic HBV infection are presented here, along with the relevant background information.
Journal ArticleDOI
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault,Natalie Bzowej,Kyong-Mi Chang,Jessica P. Hwang,Maureen M. Jonas,M. Hassan Murad +5 more
TL;DR: Aasld Guidelines for Treatment of Chronic Hepatitis B Norah Terrault;Natalie Bzowej;Kyong-Mi Chang;Jessica Hwang;Maureen Jonas;Hassan Murad; Hepatology
Journal ArticleDOI
Hepatitis B virus infection
TL;DR: Developing new therapies that can improve HBsAg clearance and virological cure is warranted because long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma.
Journal ArticleDOI
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
Yun Fan Liaw,Jia-Horng Kao,Teerha Piratvisuth,Henry Lik-Yuen Chan,Rong-Nan Chien,Chun-Jen Liu,Edward Gane,Stephen Locarnini,Seng Gee Lim,Kwang Hyub Han,Deepak Amarapurkar,Graham Cooksley,Wasim Jafri,Rosmawati Mohamed,Jin Lin Hou,Wan-Long Chuang,Laurentius A. Lesmana,Jose D. Sollano,Dong Jin Suh,Masao Omata +19 more
TL;DR: New HBV management guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy.
Journal ArticleDOI
Chronic Hepatitis B Infection: A Review
TL;DR: Antiviral treatment with either pegylated interferon or a nucleos(t)ide analogue (lamivudine, adefovir, entecavir, tenofovir disoproxil, or ten ofovir alafenamide) should be offered to patients with chronic HBV infection and liver inflammation in an effort to reduce progression of liver disease.
References
More filters
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
C.P.G.P.P. Marcellin,G.M. Dusheiko,Fabien Zoulim,Rafael Esteban,Stephanos J. Hadziyannis,Pietro Lampertico,M.P. Manns,Daniel Shouval,Cihan Yurdaydin,R.A. Craxi,Xavier Forns,Darius Moradpour,Jean-Michel Pawlotsky,Jörg Petersen,H.W.F. Easl +14 more
TL;DR: The objective of these EASL Clinical Practice Guidelines is to update recommendations for the optimal management of chronic hepatitis B (CHB) and the CPGs do not focus on prevention and vaccination.
Journal ArticleDOI
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching-Lung Lai,Daniel Shouval,Anna S. Lok,Ting-Tsung Chang,Hugo Cheinquer,Zachary Goodman,Deborah DeHertogh,R B Wilber,Richard C. Zink,Anne Cross,Richard J. Colonno,Lori Fernandes +11 more
TL;DR: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.